## REMARKS/ARGUMENTS

In accordance with the Objection to the Sequence Listing, the Specification has been amended to comply and remove all objections and errors. A computer readable form copy of the Sequence Listing has been included with this mailing. Please note that the substitute paper copy of the sequence listing and the computer readable form copy are identical and do not contain any new matter.

Applicant respectfully requests that the patent issue as soon as possible.

Respectfully submitted,

NORTHWEST PATENT LAW

John C. Hughs

Reg. No. 47,236

Tel.: (509) 332-4995




## SEQUENCE LISTING-revised 2

```
(1) GENERAL INFORMATION:
     APPLICANT: Joseph W Harding and John W Wright
  (ii) TITLE OF INVENTION: AT4 Ligands as Anti-Angiogenic and Anti-Tumor Agents
  (iii) NUMBER OF SEQUENCES: 5
  (iv) CORRESPONDENCE ADDRESS:
       (A) ADDRESSEE: Pacific Northwest Biotechnology, Inc.
       (B) STREET: SE 745 Derby Street
       (C) CITY: Pullman
       (D) STATE: Washington
       (E) COUNTRY: United States of America
       (F) ZIP: 99163
  (v) COMPUTER READABLE FORM:
       (A) MEDIUM TYPE: CD, 700MB
       (B) COMPUTER: PC
       (C) OPERATING SYSTEM: WINDOWS XP
       (D) SOFTWARE: OFFICE WORD
  (vi) CURRENT APPLICATION DATA:
       (A) APPLICATION NUMBER: 10/675,470
       (B) FILING DATE: 09/30/2003
       (C) CLASSIFICATION: 530/300
   (viii) ATTORNEY/AGENT INFORMATION:
       (A) NAME: John Hughs
       (B) REGISTRATION NUMBER:47,236
  (ix) TELECOMMUNICATION INFORMATION:
       (A) TELEPHONE: (509) 335-7927; (509) 332-3178
       (B) TELEFAX: (509) 335-4650
(2) INFORMATION FOR SEQ ID NO:1:
       SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 amino acids
       (B) TYPE: amino acid
       (D) TOPOLOGY: linear
   (ii) MOLECULE TYPE: peptide
    (v) FRAGMENT TYPE: N-terminal
    (ix) FEATURE:
       (D) OTHER INFORMATION: Xaa is norleucine
   (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
        Xaa Tyr Ile His
(2) INFORMATION FOR SEQ ID NO:2:
   (i) SEQUENCE CHARACTERISTICS:
       (A) LENGTH: 4 amino acids
       (B) TYPE: amino acid
       (D) TOPOLOGY: linear
   (ii) MOLECULE TYPE: peptide(v) FRAGMENT TYPE: N-terminal
   (ix) FEATURE:
        (D) OTHER INFORMATION: Xaa(1) is norleucine; Xaa(4) is 6-aminohexanoic
            acid; amidation
   (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
        Xaa Tyr Ile Xaa
(2) INFORMATION FOR SEQ ID NO:3:
   (i) SEQUENCE CHARACTERISTICS:
       (A) LENGTH: 6 amino acids
       (B) TYPE: amino acid
       (D) TOPOLOGY: linear
   (ii) MOLECULE TYPE: peptide
    (v) FRAGMENT TYPE: N-terminal
   (ix) FEATURE:
```

Page 1



## RAW SEQUENCE LISTING ERROR REPORT



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number:

Source:

Date Processed by STIC:

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE <u>CHECKER</u> <u>VERSION 4.2 PROGRAM</u>, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

- 1 EFS-Bio (<a href="http://www.uspto.gov/ebc/efs/downloads/documents.htm">http://www.uspto.gov/ebc/efs/downloads/documents.htm</a>, EFS Submission User Manual ePAVE)
- 2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
- Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 06/05/04):
   U.S. Patent and Trademark Office, 220 20<sup>th</sup> Street S., Customer Window, Mail Stop Sequence, Crystal Plaza Two, Lobby, Room 1B03, Arlington, VA 22202

Revised 05/17/04





IFW16

RAW SEQUENCE LISTING

DATE: 01/04/2005

PATENT APPLICATION: US/10/675,470

TIME: 10:02:47

Input Set : A:\SEQUENCE LISTING.asc Output Set: N:\CRF4\01042005\J675470.raw

## SEQUENCE LISTING

```
2 (1) GENERAL INFORMATION:
           (iii) NUMBER OF SEQUENCES: 4
            (vi) CURRENT APPLICATION DATA:
C-->
                  (A) APPLICATION NUMBER: US/10/675,470
C-->
```

(B) FILING DATE: 30-Sep-2003

Corrected Diskette Needed ERRORED SEQUENCES (2) INFORMATION FOR SEQ ID NO: 1: (i) SEQUENCE CHARACTERISTICS: 7 (A) LENGTH: 4 amino acids 8 (B) TYPE: amino acid 9 (C) STRANDEDNESS: single 10 (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide 11 (iii) HYPOTHETICAL: NO 12 13 (iv) ANTI-SENSE: NO 14 (v) FRAGMENT TYPE N-terminal 15 (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1, 16 Norleucine Tyrf le His E--> 17 19 (2) INFORMATION FOR SEQ ID NO: 2: 20 (i) SEQUENCE CHARACTERISTICS: 21 (A) LENGTH: 4 amino acids 22 (B) TYPE: amino acid 23 (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO 26 27 (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE N-terminal 28 (vi) ORIGINAL SOURCE: 29 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: 30 Norleucine Tyn-11e0 6 Aminohexanoic Acid) - amide > 31 (2) INFORMATION FOR SEQ 10 (0:3: (i) SEQUENCE CHARACTERISTICS: 35 36 (A) LENGTH: 6 amino acids 37 (B) TYPE: amino acid 38 (C) STRANDEDNESS: single 39 (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide -: Pls Use sequencing format

Per 010 Rule 5/4/05

file://C:\CRF4\OUTHOLD\VsrJ675470.htm



RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/675,470

DATE: 01/04/2005 TIME: 10:02:47

plsuse(3) letter base codes. Input Set : A:\SEQUENCE LISTING.asc Output Set: N:\CRF4\01042005\J675470.raw (A) DESCRIPTION: Norleucine(1) - Angiotensin IV 41 (iii) HYPOTHETICAL: NO 42 (iv) ANTI-SENSE: NO 43 (v) FRAGMENT TYPE: N-terminal 44 (vi) ORIGINAL SOURCE: -> 45 (ix) FEATURE: 46 (A) NAME/KEY: Modified-site 47 (B) LOCATION: N-terminal amino acid 48 (D) OTHER INFORMATION: 49 (xi) SEQUENCE DESCRIPTION: SEO ID NO: 3: 50 same er for -Norleucing-Tyr-Ile-His-Pro-Phe B--> 51 (2) INFORMATION FOR SEQ ID NO: 4: (i) SEQUENCE CHARACTERISTICS: 55 (A) LENGTH: 6 amino acids 56 57 (B) TYPE: amino acid plsusel3) lette codes. (C) STRANDEDNESS: single 58 (D) TOPOLOGY: linear 59 (ii) MOLECULE TYPE: peptide 60 (A) DESCRIPTION: Norleual (iii) HYPOTHETICAL: NO 62 (iv) ANTI-SENSE: NO 63 (v) FRAGMENT TYPE: N-terminal 64 (vi) ORIGINAL SOURCE: 65 (ix) FEATURE: 66 (A) NAME/KEY: Modified-site 67 68 (B) LOCATION: Multiple (D) OTHER INFORMATION: 70 /note= Leu3-His4 is a methylene bond 71 instead of a peptide bond. (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: 72 Norleucine Tyr-Leu-His-Pro-Phe E--> 73

- Yt: Amino acid sequence Should be grouped as:

Tyr Leu His Pro

a pls use (3) letter



VERIFICATION SUMMARY

PATENT APPLICATION: US/10/675,470

DATE: 01/04/2005 TIME: 10:02:48

Input Set : A:\SEQUENCE LISTING.asc
Output Set: N:\CRF4\01042005\J675470.raw

L:0 M:200 E: Mandatory Header Field missing, [(i) APPLICANT:] of (1) L:0 M:200 E: Mandatory Header Field missing, [(ii) TITLE OF INVENTION:] of (1) L:O M:200 E: Mandatory Header Field missing, [(A) ADDRESSEE:] of (1)(iv) L:0 M:200 E: Mandatory Header Field missing, [(B) STREET:] of (1)(iv) L:0 M:200 E: Mandatory Header Field missing, [(C) CITY:] of (1)(iv) L:0 M:200 E: Mandatory Header Field missing, [(D) STATE:] of (1)(iv) L:0 M:200 E: Mandatory Header Field missing, [(E) COUNTRY:] of (1)(iv) L:0 M:200 E: Mandatory Header Field missing, [(F) ZIP:] of (1)(iv) L:0 M:249 C: Inserted Mandatory Field, [(vi) CURRENT APPLICATION DATA:] L:0 M:249 C: Inserted Mandatory Field, [(A) APPLICATION NUMBER:] L:0 M:249 C: Inserted Mandatory Field, [(B) FILING DATE:] L:17 M:333 E: Wrong sequence grouping, Amino acids not in groups! L:17 M:330 E: (2) Invalid Amino Acid Designator, 1 L:17 M:203 E: No. of Seq. differs, LENGTH:Input:4 Found:1 SEQ:1 L:31 M:333 E: Wrong sequence grouping, Amino acids not in groups! L:31 M:330 E+ (2) Invalid Amino Acid Designator, 2 L:31 M:203 E: No. of Seq. differs, LENGTH:Input:4 Found:2 SEQ:2 L:45 M:220 C: Keyword misspelled or invalid format, [(vi) ORIGINAL SOURCE:] L:51 M:333 E: Wrong sequence grouping, Amino acids not in groups! L:51 M:330 E: (2) Invalid Amino Acid Designator, 1 L:51 M:203 E: No. of Seq. differs, LENGTH:Input:6 Found:1 SEQ:3 L:73 M:333 E: Wrong sequence grouping, Amino acids not in groups! L:73 M:330 E: (2) Invalid Amino Acid Designator, 1 L:73 M:203 E: No. of Seq. differs, LENGTH:Input:6 Found:1 SEQ:4